Burning Rock Schedules First Quarter of 2022 Earnings Release on May 31, 2022
Burning Rock Biotech Limited (NASDAQ: BNR) will release its unaudited financial results for Q1 2022 on May 31, 2022, before U.S. markets open. A conference call will be held at 8:30 a.m. ET the same day to discuss the results. Burning Rock specializes in next-generation sequencing (NGS) technology for precision oncology, including therapy selection testing and early cancer detection. Investors can access the earnings release and join the conference call via the company’s investor relations website.
- None.
- None.
GUANGZHOU, China, May 16, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2022 before the U.S. market opens on May 31, 2022. Following the release, company management will host a conference call at 8:30 a.m. ET (8:30 p.m. Hong Kong time) on the same day to discuss its financial results for the first quarter of 2022.
Details of the conference call are as follows:
| International: | +65 67135640 |
| U.S.: | +1 3322089718 |
| U.K.: | +44 2036928124 |
| Hong Kong: | +852 30186768 |
| China Mobile: | 4008209615 |
| China Landline: | 8008207535 |
| Conference ID: | 8942518 |
A replay of the conference call will be available for one week (dial-in number: +61 2 8199 0299; same conference ID as shown above).
Please visit the Company’s investor relations website at https://ir.brbiotech.com/news-events/news-releases on May 31, 2022 to view the earnings release prior to the conference call.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
For more information about Burning Rock, please visit: www.brbiotech.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
Contact: IR@brbiotech.com
FAQ
When will Burning Rock Biotech announce its Q1 2022 financial results?
What time is the conference call for Burning Rock's Q1 2022 results?
What is the stock symbol for Burning Rock Biotech?
